Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China; School of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Int Immunopharmacol. 2023 Feb;115:109650. doi: 10.1016/j.intimp.2022.109650. Epub 2023 Jan 11.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first appeared in Wuhan, China, in December 2019. The 2019 coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, has spread to almost all corners of the world at an alarming rate. Vaccination is important for the prevention and control of the COVID-19 pandemic. Efforts are underway worldwide to develop an effective vaccine against COVID-19 using both traditional and innovative vaccine strategies. Compared to other vaccine platforms, SARS-CoV-2 virus-like particles （VLPs ）vaccines, as a new vaccine platform, have unique advantages: they have artificial nanostructures similar to natural SARS-CoV-2, which can stimulate good cellular and humoral immune responses in the organism; they have no viral nucleic acids, have good safety and thermal stability, and can be mass-produced and stored; their surfaces can be processed and modified, such as the adjuvant addition, etc.; they can be considered as an ideal platform for COVID-19 vaccine development. This review aims to shed light on the current knowledge and progress of VLPs vaccines against COVID-19, especially those undergoing clinical trials.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）于 2019 年 12 月首次在中国武汉出现。由 SARS-CoV-2 引起的 2019 年冠状病毒病（COVID-19）大流行以惊人的速度蔓延到世界几乎所有角落。疫苗接种对于 COVID-19 大流行的预防和控制非常重要。全世界正在努力使用传统和创新的疫苗策略开发针对 COVID-19 的有效疫苗。与其他疫苗平台相比，SARS-CoV-2 病毒样颗粒（VLPs）疫苗作为一种新的疫苗平台具有独特的优势：它们具有类似于天然 SARS-CoV-2 的人工纳米结构，可以在机体中刺激良好的细胞和体液免疫反应；它们没有病毒核酸，具有良好的安全性和热稳定性，可以大规模生产和储存；它们的表面可以进行加工和修饰，例如添加佐剂等；它们可以被视为 COVID-19 疫苗开发的理想平台。本综述旨在阐明针对 COVID-19 的 VLPs 疫苗的现有知识和进展，特别是那些正在进行临床试验的疫苗。
